DOJ Urges Compromise In Gene Patent Appeal Brief

Law360, New York (November 1, 2010, 2:50 PM EDT) -- The U.S. Department of Justice has weighed in on the continuing battle over the patentability of human genes, telling a federal appeals court that a district judge was right to invalidate patents for isolated DNA but wrong to nix patents claiming man-made manipulations.

The presiding judge in the suit accusing Myriad Genetics Inc. of holding seven invalid patents for genes linked to breast cancer should have distinguished between those claims that merely isolated the genes and those that actually altered them, the DOJ said in an...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.